CN105873937A - 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 - Google Patents

用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 Download PDF

Info

Publication number
CN105873937A
CN105873937A CN201480071722.4A CN201480071722A CN105873937A CN 105873937 A CN105873937 A CN 105873937A CN 201480071722 A CN201480071722 A CN 201480071722A CN 105873937 A CN105873937 A CN 105873937A
Authority
CN
China
Prior art keywords
salt
nicotinamide riboside
skin
weight
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480071722.4A
Other languages
English (en)
Chinese (zh)
Inventor
安·德仁-路易斯
特洛伊·鲁尼穆斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Priority to CN201910027571.7A priority Critical patent/CN109985056A/zh
Publication of CN105873937A publication Critical patent/CN105873937A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
CN201480071722.4A 2013-10-30 2014-10-30 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物 Pending CN105873937A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910027571.7A CN109985056A (zh) 2013-10-30 2014-10-30 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361897713P 2013-10-30 2013-10-30
US61/897,713 2013-10-30
PCT/US2014/063260 WO2015066382A1 (en) 2013-10-30 2014-10-30 Nicotinamide riboside compositions for topical use in treating skin conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910027571.7A Division CN109985056A (zh) 2013-10-30 2014-10-30 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物

Publications (1)

Publication Number Publication Date
CN105873937A true CN105873937A (zh) 2016-08-17

Family

ID=53005146

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480071722.4A Pending CN105873937A (zh) 2013-10-30 2014-10-30 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物
CN201910027571.7A Pending CN109985056A (zh) 2013-10-30 2014-10-30 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910027571.7A Pending CN109985056A (zh) 2013-10-30 2014-10-30 用于在治疗皮肤病中局部使用的烟酰胺核苷组合物

Country Status (12)

Country Link
US (2) US10688118B2 (https=)
EP (1) EP3063163B1 (https=)
JP (1) JP6509844B2 (https=)
KR (3) KR20160067195A (https=)
CN (2) CN105873937A (https=)
AU (1) AU2014342185B2 (https=)
CA (1) CA2928656C (https=)
ES (1) ES2925879T3 (https=)
MX (2) MX394291B (https=)
NZ (1) NZ719328A (https=)
WO (1) WO2015066382A1 (https=)
ZA (1) ZA201603314B (https=)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913864A (zh) * 2018-08-17 2020-03-24 邦泰生物工程(深圳)有限公司 一种稳定型烟酰胺核糖组合物及其制备方法
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
CN111246838A (zh) * 2017-10-06 2020-06-05 艾克斯奥巴德蒙公司 用于将活性成分递送至皮肤的套件
CN111454311A (zh) * 2020-04-03 2020-07-28 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
WO2021073426A1 (zh) * 2019-10-17 2021-04-22 泓博元生命科技（深圳）有限公司 Nadh 及其盐在制备皮肤色素抑制剂中的应用
CN114423771A (zh) * 2019-07-19 2022-04-29 生物合成股份公司 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途
CN114933621A (zh) * 2022-04-13 2022-08-23 深圳市迪克曼生物科技有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170012449A (ko) * 2014-06-02 2017-02-02 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 결정질 베타-d-니코틴아미드 리보시드의 제조 및 용도
CA2951287A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
CN106715454B (zh) 2014-07-24 2020-06-16 格雷斯公司 烟酰胺核苷的结晶形式
KR102629310B1 (ko) 2015-03-09 2024-01-24 더블유.알. 그레이스 앤드 캄파니-콘. 니코틴아미드 리보사이드의 결정 형태
CN107531738B (zh) * 2015-03-16 2021-02-19 可劳迈戴斯有限公司 烟酸核苷或烟酰胺核苷组合物、其还原衍生物及其用途
WO2016178945A1 (en) 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
WO2016178949A1 (en) * 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving skin health and compositions therefor
WO2016178944A1 (en) 2015-05-01 2016-11-10 The Procter & Gamble Company Method of improving the appearance of skin and compositions therefor using nicotinamide riboside
JP2018517774A (ja) * 2015-06-10 2018-07-05 エリジウム・ヘルス・インコーポレイテッド ニコチンアミドリボシドおよびプテロスチルベン組成物ならびに皮膚障害の処置のための方法
US20180177703A1 (en) * 2015-06-25 2018-06-28 N.V. Perricone Llc Niacinamide Mononucleotide Formulations For Skin Aging
WO2017004101A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Skin care compositions comprising particles with nicotinamide riboside and methods of using the same
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
KR102114892B1 (ko) 2016-01-11 2020-05-26 더 프록터 앤드 갬블 캄파니 피부 상태의 치료 방법 및 그를 위한 조성물
CA3017254C (en) 2016-03-16 2023-08-22 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
US10183036B2 (en) 2016-04-20 2019-01-22 ChromaDex Inc. Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as NAD+ increasing precursors
BR112019003579A2 (pt) 2016-08-22 2019-05-21 Elysium Health, Inc. Composições de ribosídeo de nicotinamida e pterostilbeno e métodos para o tratamento dedistúrbios neurodegenerativos
CA3045876A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Scalable syntheses of nicotinoyl ribosides and reduced nic otinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
PH12019501354B1 (en) 2016-12-21 2023-04-19 Unilever Ip Holdings B V Personal care compositions with cystine
EP3558243B1 (en) 2016-12-21 2022-10-05 Unilever IP Holdings B.V. Personal care compositions comprising poorly soluble compounds
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
CN110121330B (zh) 2016-12-21 2022-04-29 联合利华知识产权控股有限公司 具有包含4-取代的间苯二酚和氨基酸的谷胱甘肽前体的个人护理组合物
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
US20200085849A1 (en) * 2017-05-18 2020-03-19 Elysium Health, Inc. Methods and compositions for improving sleep
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
WO2018237218A1 (en) 2017-06-23 2018-12-27 The Procter & Gamble Company COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE
CA3108015A1 (en) * 2017-07-28 2019-01-31 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
US11219590B2 (en) * 2017-09-14 2022-01-11 Megumi Tanaka Anti-aging agent and anti-aging method
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE
KR20210011964A (ko) 2018-07-03 2021-02-02 더 프록터 앤드 갬블 캄파니 피부 병태를 치료하는 방법
KR102060374B1 (ko) * 2018-12-14 2019-12-30 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
KR102315139B1 (ko) 2019-12-17 2021-10-20 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
CN111184732B (zh) * 2020-03-04 2023-09-08 武汉华纳联合药业有限公司 一种复合组合物制剂及其制备方法和皮肤炎症中的应用
WO2021234009A1 (fr) * 2020-05-20 2021-11-25 Nuvamid Sa Compositions cosmetiques anti-age comprenant du nmn
FR3110410A1 (fr) * 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
CN115843238B (zh) 2020-06-01 2025-06-10 宝洁公司 改善维生素b3化合物渗透到皮肤中的方法
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
CN111632049A (zh) * 2020-06-09 2020-09-08 西北农林科技大学 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方
US20230263817A1 (en) * 2020-08-28 2023-08-24 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
EP4029496A1 (en) * 2021-01-18 2022-07-20 Universitat de València Pterostilbene and silibinin for preventing, ameliorating or reducing radiation-induced diseases
WO2022157173A1 (en) * 2021-01-19 2022-07-28 Biosynth Ag Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt
US12150461B2 (en) * 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
KR102784901B1 (ko) * 2022-06-23 2025-03-21 제너럴바이오(주) Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
US20120172584A1 (en) * 2005-11-18 2012-07-05 Cornell University Nicotyl riboside compositions and methods of use
CN103055313A (zh) * 2005-07-07 2013-04-24 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3780257B2 (ja) * 2001-02-22 2006-05-31 ユニリーバー・ナームローゼ・ベンノートシヤープ 油及び脂肪を抑制する皮膚用組成物
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
EP2805719A1 (en) 2005-03-30 2014-11-26 Glaxosmithkline LLC Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
EP2117652B1 (en) * 2007-03-12 2013-09-25 DSM IP Assets B.V. Cosmetic compositions
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
EP2522355B1 (en) * 2010-01-06 2018-02-21 Kabushiki Kaisha Yakult Honsha Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
CN103055313A (zh) * 2005-07-07 2013-04-24 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
US20120172584A1 (en) * 2005-11-18 2012-07-05 Cornell University Nicotyl riboside compositions and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DEVITA SURJANA，等: "Role of Nicotinamide in DNA Damage,Mutagenesis, and DNA Repair", 《JOURNAL OF NUCLEIC ACIDS》 *
KATIE M. DIXON，等: "Vitamin D and Death by Sunshine", 《INT.J.MOL.SCI.》 *
LEE ANN APPLEGATE，等: "IDENTIFICATION OF THE MOLECULAR TARGET FOR THE SUPPRESSION OF CONTACT HYPERSENSITIVITY BY ULTRAVIOLET RADIATION", 《J.EXP.MED.》 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111246838A (zh) * 2017-10-06 2020-06-05 艾克斯奥巴德蒙公司 用于将活性成分递送至皮肤的套件
CN111246838B (zh) * 2017-10-06 2024-01-26 艾克斯奥巴德蒙公司 用于将活性成分递送至皮肤的套件
CN110913864A (zh) * 2018-08-17 2020-03-24 邦泰生物工程(深圳)有限公司 一种稳定型烟酰胺核糖组合物及其制备方法
CN110913864B (zh) * 2018-08-17 2022-12-13 邦泰生物工程(深圳)有限公司 一种稳定型烟酰胺核糖组合物及其制备方法
US12344629B2 (en) 2019-07-19 2025-07-01 Biosynth Ag Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CN114423771A (zh) * 2019-07-19 2022-04-29 生物合成股份公司 制备烟酰胺呋喃核糖苷盐的方法、烟酰胺呋喃核糖苷盐本身及其用途
WO2021073426A1 (zh) * 2019-10-17 2021-04-22 泓博元生命科技（深圳）有限公司 Nadh 及其盐在制备皮肤色素抑制剂中的应用
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
CN111454311B (zh) * 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
US11505570B2 (en) 2020-04-03 2022-11-22 Shenzhen Dieckmann Tech Co., Ltd Organic acid salt of nicotinamide riboside, composition including organic acid salt, and preparation methods of organic acid salt and composition
KR20220156642A (ko) * 2020-04-03 2022-11-25 썬전 디에크만 테크 컴퍼니 리미티드 니코틴아미드 리보사이드의 유기산염 및 이의 조성물 및 제조방법
AU2020440743B2 (en) * 2020-04-03 2024-02-15 Shenzhen Dieckmann Tech Co. Ltd Organic acid salt of nicotinamide riboside, composition thereof and preparation method therefor
WO2021196349A1 (zh) * 2020-04-03 2021-10-07 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
KR102591687B1 (ko) 2020-04-03 2023-10-20 썬전 디에크만 테크 컴퍼니 리미티드 니코틴아미드 리보사이드의 유기산염 및 이의 조성물 및 제조방법
CN111454311A (zh) * 2020-04-03 2020-07-28 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
CN114933621A (zh) * 2022-04-13 2022-08-23 深圳市迪克曼生物科技有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途
CN116621898A (zh) * 2022-04-13 2023-08-22 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途

Also Published As

Publication number Publication date
MX385305B (es) 2025-03-18
CN109985056A (zh) 2019-07-09
KR20160067195A (ko) 2016-06-13
CA2928656C (en) 2020-07-28
JP2016538271A (ja) 2016-12-08
ES2925879T3 (es) 2022-10-20
MX2021009652A (es) 2022-07-26
US20200289536A1 (en) 2020-09-17
US11033568B2 (en) 2021-06-15
KR20220098049A (ko) 2022-07-08
EP3063163B1 (en) 2022-08-10
MX2016005574A (es) 2016-12-09
US10688118B2 (en) 2020-06-23
EP3063163A4 (en) 2017-05-10
JP6509844B2 (ja) 2019-05-08
NZ719328A (en) 2022-04-29
WO2015066382A1 (en) 2015-05-07
CA2928656A1 (en) 2015-05-07
MX394291B (es) 2025-03-24
KR20210107895A (ko) 2021-09-01
AU2014342185B2 (en) 2019-01-03
ZA201603314B (en) 2017-09-27
EP3063163A1 (en) 2016-09-07
US20160250241A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
US11033568B2 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
AU2014342185A1 (en) Nicotinamide riboside compositions for topical use in treating skin conditions
CN104997803B (zh) 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法和组合物
JP5570992B2 (ja) 皮膚病又は皮膚病変の治療方法及び組成物
US20090324705A1 (en) Phytonutrient compositions for topical use
BRPI0923534B1 (pt) composição cosmética de emulsão de óleo em água não formadora de espuma e uso da mesma
Farris Cosmeceutical vitamins: vitamin C
US9962360B2 (en) Compositions and methods for enhancing hair growth, promoting skin regeneration, and wound healing
AU2019204136B2 (en) Compositions and methods for treating skin conditions using light and glucosamine hydrochloride
US20160354411A1 (en) Olivamine-induced improvement in endothelial cells viability and function
CN113038920A (zh) 用于治疗美学皮肤病症的铁螯合化合物
HK40011054A (en) Nicotinamide nucleoside composition for topical use in the treatment of dermatosis
US20110274775A1 (en) Extracts of southernwood and topical uses thereof
CA3193642A1 (en) Compositions and methods for the treatment of hair loss and other conditions
CA3084891A1 (en) Compositions and methods for treating skin conditions using infrared light and resorcinols
US20250114362A1 (en) Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
JP2007153863A (ja) 毛髪改善外用剤
Zhang et al. Anti-aging products and medical cosmeceuticals for skin photoaging
WO2026080779A2 (en) Topical compositions of thyrotropin-releasing hormone and uses thereof
US20210346380A1 (en) Treatment of skin disorders with compositions comprising an egfr inhibitor
Casale et al. Clinical role of oral vitamin C and E therapy in skin and hair disorders: A systematic review

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160817